To the Editor: Since 2007, a new cardiovirus, named Saffold virus (SAVF), has been isolated from human specimens in the United States, Canada, the Netherlands, and People’s Republic of China (1–4). Concurrent investigations also showed that SAVF could be detected in feces and respiratory secretions of children in other countries, and genetic analysis showed the circulation of different genetic lineages of SAFVs in various parts of the world. This new virus belongs to the genus Cardiovirus, in the family Picornaviridae (5). Here we report isolation of a new SAFV in Malaysia, designated SAFV-Penang to reflect the locality of isolation in Malaysia.

A 5-year-old girl was brought to a government outpatient clinic on November 18, 2009, with reported fever and sore throat for 3 days. The fever was described as of high grade with occasional episodes of rigor, accompanied by profuse sweating and myalgia, lethargy, and loss of appetite. The child had nasal blockage, mild runny nose, and dry cough. She vomited twice on day 3 of illness and had abdominal pain but no diarrhea.

There was no history of similar illness affecting other family members, who lived in a semirural area within the state of Penang, Malaysia. Acute pharyngitis/diarrhea-like illness was provisionally diagnosed, and a throat swab specimen was collected in virus transport medium for virus isolation by using established procedures (6).

The throat swab sample was treated with antimicrobial drugs for 1 h before the cells were added to MDCK, Vero, and Hep-2 cells. On the fifth day postinoculation (dpi), a lytic form of cytopathic effect (CPE), similar to the type of CPE from enterovirus infection, was noted in Hep-2 but not in Vero or MDCK cells. The progress of CPE was slow, and full CPE was achieved on 9 dpi. On 8 dpi, a 0.5-mL aliquot containing infected Hep-2 cell suspension was removed and processed for indirect immunofluorescence assay by using a panel of commercial typing monoclonal antibodies for human enteroviruses. The infected Hep-2 cells reacted strongly with broad type-specific monoclonal antibodies (data not shown).

After 3 passages in Hep-2 cells, culture supernatant was subsequently passed into Vero cells. After an additional 3 passages, the virus was fully adapted to grow in Vero cells and was able to induce visible CPE 1 dpi and full CPE by 4 dpi.

Partial genome sequence of the virus was initially obtained by using a random priming and amplification method as described (7). Full-length sequence was then determined by using primers designed according to the partial genome sequences of SAFV-Penang and genome sequences of other SAFV strains available in GenBank (primer sequences are available on request). The viral genome of SAFV-Penang is 8,073 nt.

---

**Saffold Virus Infection in Children, Malaysia, 2009**

A 5-year-old girl was brought to a government outpatient clinic on November 18, 2009, with reported fever and sore throat for 3 days. The fever was described as of high grade with occasional episodes of rigor, accompanied by profuse sweating and myalgia, lethargy, and loss of appetite. The child had nasal blockage, mild runny nose, and dry cough. She vomited twice on day 3 of illness and had abdominal pain but no diarrhea.

There was no history of similar illness affecting other family members, who lived in a semirural area within the state of Penang, Malaysia. Acute pharyngitis/diarrhea-like illness was provisionally diagnosed, and a throat swab specimen was collected in virus transport medium for virus isolation by using established procedures (6).

The throat swab sample was treated with antimicrobial drugs for 1 h before the cells were added to MDCK, Vero, and Hep-2 cells. On the fifth day postinoculation (dpi), a lytic form of cytopathic effect (CPE), similar to the type of CPE from enterovirus infection, was noted in Hep-2 but not in Vero or MDCK cells. The progress of CPE was slow, and full CPE was achieved on 9 dpi. On 8 dpi, a 0.5-mL aliquot containing infected Hep-2 cell suspension was removed and processed for indirect immunofluorescence assay by using a panel of commercial typing monoclonal antibodies for human enteroviruses. The infected Hep-2 cells reacted strongly with broad type-specific monoclonal antibodies (data not shown).

After 3 passages in Hep-2 cells, culture supernatant was subsequently passed into Vero cells. After an additional 3 passages, the virus was fully adapted to grow in Vero cells and was able to induce visible CPE 1 dpi and full CPE by 4 dpi.

Partial genome sequence of the virus was initially obtained by using a random priming and amplification method as described (7). Full-length sequence was then determined by using primers designed according to the partial genome sequences of SAFV-Penang and genome sequences of other SAFV strains available in GenBank (primer sequences are available on request). The viral genome of SAFV-Penang is 8,073 nt.
(full sequence deposited in GenBank under accession no. HQ162476).

As for other SAFVs, a single long open reading frame of 2,295 aa was detected. Phylogenetic analysis based on the complete amino acid sequences of the polyproteins of different SAFVs indicated that SAFV-Penang is a type 3 SAFV (8). It is most closely related to the SAFV-3 isolated in the Netherlands in 2007.

To determine the prevalence of SAFV infection among children in Malaysia, we conducted a seroprevalence study by using 400 serum samples collected during 2009 from children 10–12 years of age under the national hepatitis B postvaccination serosurvey. The serum panel comprised 80 samples containing equal numbers of boys and girls from each of the 5 states: Penang (northwestern), Selangor (central-western), and Kelantan (northeastern) of peninsular Malaysia, and Sabah and Sarawak of eastern Malaysia in Borneo Island. Screening for SAFV-specific antibodies was conducted by using an indirect immunofluorescence antibody test on SAFV-infected Vero cells as described (9). The results (Table) indicated that >70% of schoolchildren surveyed had been exposed to the virus. The seropositive rate ranged from 67.5% (Penang) to 75.0% (Kelantan and Sabah), with no significant difference among different parts of the country (χ² = 1.60, df = 4, p = 0.8091). The seropositive rate did not differ significantly by sex (χ² = 0.32, p = 0.5734).

In summary, a new SAFV was discovered in Malaysia by direct virus isolation during an investigation of a febrile patient. Subsequent serologic study indicated that a high percentage of children 10–12 years of age had been exposed to this virus. Further study is required to determine the public health implications of SAFV infection in Southeast Asia, especially in cases in which co-infection with other pathogens might potentially lead to different clinical outcomes.

| State of residence | No. children | No. positive serum samples† | Total no. (%) |
|-------------------|--------------|----------------------------|---------------|
| **Penang**        |              |                            |               |
| M                 | 40           | 21                         | 28 (70.0)     |
| F                 | 40           | 19                         | 26 (65.0)     |
| Total             | 80           | 40                         | 54 (67.5)     |
| **Kelantan**      |              |                            |               |
| M                 | 40           | 16                         | 29 (72.5)     |
| F                 | 40           | 18                         | 31 (77.5)     |
| Total             | 80           | 34                         | 60 (75.0)     |
| **Selangor**      |              |                            |               |
| M                 | 40           | 16                         | 32 (80.0)     |
| F                 | 40           | 22                         | 27 (67.5)     |
| Total             | 80           | 38                         | 59 (73.8)     |
| **Sabah**         |              |                            |               |
| M                 | 40           | 16                         | 29 (72.5)     |
| F                 | 40           | 24                         | 31 (77.5)     |
| Total             | 80           | 40                         | 60 (75.0)     |
| **Sarawak**       |              |                            |               |
| M                 | 40           | 22                         | 31 (77.5)     |
| F                 | 40           | 19                         | 28 (70.0)     |
| Total             | 80           | 41                         | 59 (73.8)     |

†The degree of positive reactivity was classified into 3 groups: weak (titer 0–40), medium (titer 80–160), and strong (titer 320–1,280) according to the staining intensity on SAFV-infected Vero cells (data not shown). The classification was further confirmed by correlation with virus neutralizing titer from 20 samples in each group, with + samples having a titer of 0–40, ++ samples 80–160, and +++ samples 320–1,280, respectively.

This work was supported in part by research grants from the International Medical University of Malaysia and the Commonwealth Scientific and Industrial Research Organisation Livestock Industries, Australian Animal Health Laboratory.

Kaw Bing Chua, Kenny Voon, Meng Yu, Wan Nor Azlina Wan Ali, Abdul Rasid Kasri, and Lin-Fa Wang

Author affiliations: National Public Health Laboratory, Sungai Buloh, Selangor, Malaysia (K.B. Chua, W.N.A.W. Ali, A.R. Kasri); International Medical University, Bukit Jalil, Kuala Lumpur, Malaysia (K.B. Chua, K. Voon); and Australian Animal Health Laboratory, Geelong, Victoria, Australia (M. Yu, L.-F. Wang)

DOI: 10.3201/eid1708.101380

References

1. Jones MS, Lukashov VV, Ganacl RD, Schnurr DP. Discovery of a novel human picornavirus in a stool sample from a pediatric patient presenting with fever of unknown origin. J Clin Microbiol. 2007;45:2144–50. doi:10.1128/JCM.00174-07

2. Abed Y, Boivin G. New Saffold cardioviruses in 5 children, Canada. Emerg Infect Dis. 2008;14:834–6.

3. Zoll J, Erkens Hulshof S, Lanke K, Verduyn Lunel F, Melschers WJ, Schoondermark-van den E, et al. Saffold virus, a human Theiler’s-like cardiovirus, is ubiquitous and causes infection early in life. PLoS Pathog. 2009;5:e1000416. doi:10.1371/journal.ppat.1000416

4. Chiu CY, Greniger AL, Chen EC, Haggerty TD, Parsonnet J, Delwart E, et al. Cultivation and serological characterization of a human Theiler’s-like cardiovirus associated with diarrheal disease. J Virol. 2010;84:4407–14. doi:10.1128/JVI.02536-09

5. Racanielle VR. Picornaviridae: the viruses and their replication. In: Knipe DM, Griffin DE, Lamb RA, Straus SE, Howley PM, Martin MA, et al., editors. Fields virology. Philadelphia (PA): Lippincott Williams & Wilkins; 2007. p. 795–842.

6. Chua KB, Cramer G, Huyatt A, Yu M, Tompang MR, Rosli J, et al. A previously unknown reovirus of bat origin is associated with an acute respiratory disease in humans. Proc Natl Acad Sci U S A. 2007;104:11424–9. doi:10.1073/pnas.0701372104

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 8, August 2011
Human Bocavirus DNA in Paranasal Sinus Mucosa

To the Editor: Human bocavirus (HBoV) is a newly described parvovirus for which pathogenic potential has not clearly been elucidated (1). Recent findings suggest that HBoV may establish persistent infection of mucosal lymphocytes or contribute to tonsillar hyperplasia in children (2). In previous reports, we described prolonged HBoV DNA detection in immunocompromised children (3,4). Partial sequencing of the VP1 gene of HBoV from bronchoalveolar lavage fluid, plasma, and sphenoid sinus samples showed 100% identity, which suggested persistence of the same HBoV strain over a 5-month period (3). It remains speculative, however, whether paranasal sinus mucosa represents a site of HBoV persistence. To clarify this, we analyzed samples of paranasal mucosal tissue and nasal polyps from patients with chronic sinusitis for respiratory viruses and atypical bacteria.

A total of 102 tissue samples were obtained from 88 patients (median age 48.5 years, range 13.3–88.1 years) from July 2009 through September 2010 after elective surgery. Indication for surgery was established by otorhinolaryngologists. The most common indication was chronic sinusitis. No patients displayed acute respiratory symptoms at the time of surgery. To detect asymptomatic shedding in the upper respiratory tract and viremia, we collected nasal swabs and EDTA-blood samples concurrently. The study protocol was approved by the Ethics Committee of the University of Freiburg. Informed written consent was obtained from all study participants.

Approximately 25 mg of each tissue specimen was used for nucleic acid extraction by using an RNeasy Mini Kit, as described (3) (QIAGEN, Hamburg, Germany). To provide evidence that the QIAGEN RNeasy kit is also suitable for DNA extraction, we spiked HBoV negative samples with different amounts of HBoV DNA before extraction of nucleic acids was done with either the QIAGEN RNeasy Kit or DNA Blood Kit (QIAGEN). Extracted nucleic acids were then subjected to real-time PCR by using primers specific for HBoV. Minimal differences (±1 cycle threshold [Ct] value) in the HBoV PCR were detected; the QIAGEN RNeasy Kit was therefore used throughout the study (data not shown). Nasal swabs and EDTA-blood were purified by using a QIAamp MinElute Virus Spin Kit (QIAGEN). Multiplex PCR for respiratory viruses (Fast-track Diagnostics, Junglinster, Luxembourg) was conducted to detect influenza A (including pandemic [H1N1] 2009) and B viruses; respiratory syncytial virus; human metapneumovirus; HBoV; parainfluenza virus 1–4; human coronaviruses HKU1, NL63, 229E, and OC43; human rhinoviruses; human enteroviruses and parechoviruses; and adenoviruses. Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila, and Bordetella pertussis were analyzed as described (6–8).

A single virus was detected in 22/102 (21.5%) tissue specimens, with HBoV being the most frequent (18/102, 17.6%), followed by rhinovirus (2/102, 1.9%), coronavirus 229E, and influenza A pandemic (H1N1) 2009 virus (1/102, 0.9%). HBoV was detected in specimens collected during July–September (13/18) and during February and March (5/18). All positive results were confirmed by single real-time PCR (9). For 14 patients, 2 different mucosal samples were tested and gave identical results. No multiple viral infections and no bacteria were detected. Median patient age was 51.2 years (range 14.4–74.2 years) for HBoV-positive and 47.6 years (range 13.3–88.1 years) for HBoV-negative samples. Cτ analysis in single real-time PCR revealed a median Cτ of 31 (range 28–38), corresponding to 200 genome equivalents/10⁶ cells (range 3–1.8 × 10⁴ copies/10⁶ cells). No correlation between Cτ value and patients’ age was observed (r² = 0.008; data not shown). No underlying disease was diagnosed for 13/18 HBoV-positive patients, whereas 2/18 and 3/18 patients had chronic obstructive pulmonary and oncologic disease, respectively.

Nasal swabs and EDTA-blood samples were obtained from 17/18 and 7/18 HBoV-positive patients, respectively. No HBoV was detected in any swabs or EDTA-blood samples available, indicating no virus shedding in the respiratory tract and no viremia. However, the 2 patients with rhinovirus-positive samples obtained from biopsy also had rhinovirus RNA detectable in nasal swabs, suggesting rhinovirus infection. Unfortunately, no nasal swab was available from the 2 patients whose sinus biopsy samples...